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Background. The pathophysiology of hemolytic uremic syn-
drome (HUS) is incompletely established. Based on clinical
studies demonstrating the presence of prothrombotic plasma
markers in patients with HUS, we hypothesized that Shiga toxin
might cause activation of the coagulation pathway by augment-
ing tissue factor, the major initiator of coagulation.
Methods. Human proximal tubular epithelial cells (PTECs)
[human kidney-2 (HK-2 cells)] were exposed to Shiga toxin-1,
and expression of tissue factor, cell detachment, protein synthe-
sis, caspase-3 activity, and Shiga toxin-1 binding were examined.
Results. HK-2 cells expressed constitutive surface tissue fac-
tor activity and increased their tissue factor expression upon ex-
posure to Shiga toxin-1. Shiga toxin-1 bound to HK-2 cells and
inhibited protein synthesis. The up-regulation of tissue factor
was dose- and time-dependent and strongly correlated with cell
detachment and increase in caspase-3 activity caused by Shiga
toxin-1 exposure. A general caspase inhibitor simultaneously
inhibited HK-2 cell detachment and tissue factor up-regulation
while mutant Shiga toxin-1 neither caused cell detachment, pro-
tein synthesis inhibition, nor increase in tissue factor activity.
Tissue factor activity elicited by Shiga toxin-1 was abrogated by
a monoclonal antitissue factor antibody. Calphostin C, a protein
kinase C (PKC) inhibitor, partially blocked tissue factor up-
regulation, indicating possible involvement of PKC-dependent
mechanism.
Conclusion. These data, taken together, suggest a strong link
between Shiga toxin–induced up-regulation of tissue factor ac-
tivity, cytotoxicity, and apoptosis in HK-2 cells. The proximal
tubule is a target of Shiga toxin in HUS, and it seems plausible
that injured proximal tubular cells trigger the activation of the
coagulation system, the formation of intrarenal platelet-fibrin
thrombi, and the development of acute renal failure in HUS.
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Hemolytic uremic syndrome (HUS), a thrombotic mi-
croangiopathy, is characterized by nonimmune hemolytic
anemia, thrombocytopenia, and acute renal failure [1].
The most common form of HUS is diarrhea-associated
HUS, an important complication of hemorrhagic coli-
tis caused by Shiga toxin-producing Escherichia coli [2].
Shiga toxin is considered the major cause of the tissue
damage that occurs during the course of HUS [1, 3]. The
most widely recognized tissue damage occurs within the
kidney [1]. Glomerular endothelial cell swelling and de-
tachment from the basement membrane, proximal tubu-
lar epithelial cell (PTEC) injury, mesangial expansion,
and mesangiolysis have been observed, along with apop-
tosis or necrosis of glomerular and tubular cells [1, 3]. In
the most severe cases, extensive cortical necrosis ensues
[3].
The presence of localized platelet-fibrin thrombi is the
most prominent hallmark of the intrarenal pathology in
HUS, suggesting activation of coagulation and/or a de-
crease in fibrinolytic potential. Several authors reported
that the levels of thrombin-antithrombin complexes, pro-
thrombin fragment 1 + 2, and D-dimer (a product of the
fibrinolysis of cross-linked fibrin) are higher in children
with HUS as compared to children with acute renal fail-
ure from other causes [4, 5]. Recent work revealed high
levels of plasminogen activator inhibitor type 1 (PAI-1)
in HUS, indicating substantial inhibition of fibrinolysis
[6]. Chandler et al [7] showed that HUS was preceded
by thrombin generation and inhibition of fibrinolysis.
Despite existing clinical studies, the mechanism of induc-
tion of a procoagulant state by Shiga toxin is only par-
tially understood. A recent study suggested that Shiga
toxin–induced decrease of thrombomodulin expression
in glomerular endothelial cells might contribute to the lo-
cal procoagulant state observed in HUS [8]. Tissue factor,
a 47 kD transmembrane glycoprotein, is widely accepted
as the initiator of coagulation and might play a central
role in the procoagulant state in HUS [9]. Kamitsuji et al
[10] reported elevated levels of circulating tissue factor
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in children with HUS, and our group has demonstrated
that Shiga toxin induces up-regulation of tissue factor on
human glomerular endothelial cells in the setting of prior
cytokine activation [11].
Although glomerular endothelial cell injury is consid-
ered central to the pathophysiology of HUS [1, 3], this
injury depends on the concerted actions of Shiga toxin
and inflammatory mediators, including bacterial products
such as lipopolysaccharide (LPS) and cytokines such as
tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-
1), which are believed to induce globotriaosyl ceramide
(Gb3) receptors on the surface of glomerular endothelial
cells, to which Shiga toxin binds [12–15]. On the other
hand, Gb3 receptors are prominent in renal tubules [16–
18], and proximal tubular cells are exquisitely sensitive to
Shiga toxin undergoing apoptosis when exposed to Shiga
toxin in vitro [18–22]. Proximal tubular damage is evident
in renal tissue during the early stages of HUS, raising
the possibility that proximal tubules may be an impor-
tant early target of Shiga toxin action [18–21]. Moreover,
PTECs are a rich source of tissue factor and also produce
tissue factor pathway inhibitor (TFPI) [23, 24], which, to-
gether with tissue factor, potentially regulates clotting in
the microenvironment of renal tubules. Since tissue factor
could be a major inducer of the thrombogenesis observed
in HUS, and proximal tubular cells are a target of Shiga
toxin in the kidney, we examined the role of proximal
tubular cells in expressing tissue factor by studying their
tissue factor functional activity with and without expo-
sure to Shiga toxin.
METHODS
Reagents
Keratinocyte serum-free medium, human recombinant
epidermal growth factor 1-53 and bovine pituitary ex-
tract were obtained from Gibco/Invitrogen (Carlsbad,
CA, USA). Penicillin/streptomycin was purchased from
BioWhittaker (Walkersville, MD, USA). Sterile tissue
culture plasticware was purchased from Falcon Plas-
tics (Cockeysville, MD, USA). Fibronectin was ob-
tained from Becton Dickinson Biosciences (San Jose,
CA, USA). Purified Shiga toxin-1, mutant Shiga toxin-
1 (a toxin with a substitution mutation in the active
site, Stx1E167D) and rabbit anti-Shiga toxin-1 antibody
were kindly provided by Dr. Cheleste Thorpe (Tufts-
New England Medical Center, Boston, MA, USA). A
mouse monoclonal antibody against human tissue fac-
tor (antitissue factor) was provided as a courtesy by Dr.
Yale Nemerson (Mt. Sinai Medical Center, New York,
NY, USA). Human coagulation factors VII and X were
obtained from Enzyme Research Laboratories (South
Bend, IN, USA). Purified factor Xa was kindly pro-
vided by Dr. Arabinda Guha (Mt. Sinai Medical Center,
New York, NY, USA). The human recombinant cy-
tokine TNF-a and the general caspase inhibitor Z-VAD-
FMK were purchased from R&D Systems (Minneapo-
lis, MN, USA). Caspase-3 colorimetric protease assay kit
was purchased from Medical and Biological Laborato-
ries (Woburn, MA, USA). Spectrozyme Xa and rabbit
antihuman TFPI (anti-TFPI) IgG were purchased from
American Diagnostica (Greenwich, CT, USA). Fluores-
cein isothiocyanate (FITC)-conjugated goat antirabbit
IgG was obtained from Accurate & Scientific (Westbury,
NY, USA). 3H-leucine was obtained from Perkin-Elmer
(Boston, MA, USA). The scintillation cocktail was pur-
chased from Beckman (Fullerton, CA, USA). All other
reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Cell culture
Renal PTECs. Human kidney-2 (HK-2) cells, an im-
mortalized renal PTEC line (CRL-2190) derived from
normal adult human kidney tissue, were a kind gift of
Dr. Howard Trachtman (Schneider Children’s Hospital
of the North Shore-Long Island Jewish Health System,
New Hyde Park, NY, USA). These cells were grown
in complete medium consisting of keratinocyte serum-
free medium, supplemented with recombinant epider-
mal growth factor (5 ng/mL), bovine pituitary extract
(40 mg/mL), and penicillin/streptomycin (10 lg/mL).
Cells were incubated at 37◦C in a humidified atmosphere
of 5% CO2-95% air with medium changed every 2 days;
cells were used between the 25th and 40th passage. All
experiments were performed after cells had reached con-
fluence (generally 5 to 7 days after passage) as judged by
phase contrast microscopy.
Experimental conditions
HK-2 cells were plated on 12-well tissue culture plates
that had been precoated with fibronectin (adsorbed from
a 10 lg/mL solution for 1 hour at room temperature) and
were grown to confluence in complete medium. At con-
fluence, they were exposed to Shiga toxin-1 (complete
medium containing Shiga toxin-1, 10−15 mol/L to 10−9
mol/L) for 2, 4, 6, 8, 10, 12, 22, 48, 72, and 96 hours to study
their surface tissue factor activity as a function of Shiga
toxin-1 concentration and duration of exposure. The con-
centrations of Shiga toxin-1 were chosen based both on
the observations of Yagi et al [25] who detected Shiga
toxin concentrations of this order of magnitude in plasma
of patients with HUS, and on our observations that Shiga
toxin-1 in concentration of 10−11 mol/L enhanced tissue
factor activity on TNF-a stimulated human glomerular
endothelial cells [11]. HK-2 cells were also studied fol-
lowing activation with TNF-a (20 ng/mL) for the same
time periods. TNF-a was chosen because it has been im-
plicated in the pathogenesis of HUS as an inflammatory
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mediator and is a well-known inducer of tissue factor ex-
pression in endothelial cells and monocytes [26].
Unstimulated cells served as control (complete
medium with no additives) in all experiments performed.
In order to identify the existence of possible synergy
between Shiga toxin-1 and TNF-a in the expression of
tissue factor surface activity, HK-2 cells were exposed
to Shiga toxin-1 (10−15 mol/L to 10−9 mol/L), or TNF-a
(20 ng/mL) or a combination of TNF-a (20 ng/mL) and
Shiga toxin-1 (10−15 mol/L to 10−9 mol/L) for 22 hours. In
order to assess the possible role of N-glycosidase activity
of Shiga toxin-1 on tissue factor production, we exposed
HK-2 cells for 22 hours to Shiga toxin-1 (10−15 mol/L to
10−9 mol/L), or to mutant Shiga toxin-1 (10−15 mol/L to
10−9 mol/L), in which a substitution mutation in the ac-
tive site (E167D) renders the mutant toxin approximately
500-fold less enzymatically active than (wild-type) Shiga
toxin-1. In order to assess whether the protein kinase C
(PKC) pathway is involved, HK-2 cells were incubated
with Shiga toxin-1 (10−9 mol/L), or phorbol myristate ac-
etate (PMA) (10−8 mol/L), a PKC pathway agonist, or
calphostin C (10−6 mol/L), a selective inhibitor of the
PKC pathway, or a combination of calphostin C plus ei-
ther Shiga toxin-1 or PMA for 22 hours. To examine the
role of apoptosis in the induction of tissue factor sur-
face activity in HK-2 cells, HK-2 monolayers were ex-
posed to Shiga toxin-1 (10−13 mol/L to 10−9 mol/L) for
22 hours with or without the presence of the general cas-
pase inhibitor Z-VAD-FMK (40 lmol/L to 100 lmol/L).
Dilutions of all reagents were prepared using complete
medium.
Quantification of cell detachment
At the end of each experiment, HK-2 monolay-
ers were examined by phase contrast microscopy
for the presence of detached cells. Medium was re-
moved for counting of any detached cells. Remaining
adherent cells were removed by exposure to trypsin-
ethylenediaminetetraacetic acid (EDTA) (0.25%),
followed by quenching with complete medium and
centrifugation at 200g for 5 minutes at 4◦C. To ensure
complete harvesting of adherent cells, plates were ex-
amined by phase contrast microscopy. Cells were
resuspended in complete medium and counted twice
in a hemocytometer. Cell integrity of spontaneously
detached and harvested cells was also assessed after
incubation with trypan blue at room temperature.
Reported cell numbers denote the number of adherent
cells per well of a tissue culture plate.
3H-leucine incorporation
The standard procedure of incorporation of 3H-leucine
was employed to assess whether Shiga toxin-1 inhibited
protein synthesis in HK-2 cells. HK-2 monolayers were
exposed for 22 hours to (wild-type) Shiga toxin-1 (10−13
mol/L to 10−9 mol/L), or mutant Shiga toxin-1 (10−11
mol/L), or TNF-a (20 ng/mL). At the end of exposure
period, and after washing twice with phosphate-buffered
saline (PBS), medium containing 3H-leucine (1 lCi/mL)
was added for 5 hours. Then, cells were washed twice with
ice-cold PBS to terminate isotope uptake, and 3H-labeled
cellular proteins were precipitated by trichloroacetic acid
(10%). Sodium hydroxide (0.25 mol/L) was applied for
2 hours and then neutralized with harvest buffer, con-
sisting of two parts of Tris (1 mol/L) and one part of
hydrochloric acid (2.5 mol/L). Aliquots of 50 lL were
transferred into scintillation vials with 4 mL scintillation
cocktail and counts per minute were determined with a
Packard b-counter (Downers Grove, IL, USA). Each vial
was counted for 1 minute.
Chromogenic assay for factor Xa production
Functional tissue factor on adherent or detached cells
was measured as activated clotting factor X (factor Xa)
generation using an amidolytic technique [27]. After re-
moval of medium containing any detached cells, adherent
cells were washed once with Hepes buffer [Hepes (0.01
mol/L), NaCl (0.14 mol/L), and CaCl2 (0.005 mol/L), pH
7.4]. Medium removed from each well was centrifuged at
200g for 5 minutes at 4◦C for isolation of any detached
cells. The adherent cells or the sedimented detached cells
were then incubated for 60 minutes at 37◦C with a “reac-
tion complex” (400 lL/well) consisting of Hepes buffer
with 10 nmol/L of factor VII, 100 nmol/L of factor X and
human serum albumin (0.1%). Aliquots of 360 lL postin-
cubation reaction complex were mixed with an equal vol-
ume of 75 mmol/L of EDTA to inhibit further activation
of factor X and then incubated with spectrozyme Xa (0.5
mmol/L) at 37◦C for 30 minutes. To block further action of
factor Xa on the chromogenic substrate, acetic acid (30%,
one part to five parts reaction complex) was added. Blank
wells without cells were used to measure and deduct the
average background from control and test wells. Samples
were read in a microplate reader (Bio-Rad Laboratories,
Hercules, CA, USA) at 405 nm absorbance of free chro-
mophore; a calibration curve had been constructed by us-
ing known concentrations of purified factor Xa. Results
are expressed in fmol/minute × cm2; where cm2 is the
surface area of HK-2 cells exposed to each experimen-
tal condition. This approach acknowledges the possibil-
ity that cell fragments or subepithelium may contribute
to the measured tissue factor activity. Normalization of
data by adherent cell count (fmol/minute × 100,000 cells)
was also calculated; this approach emphasizes the role of
distinct cells and implicitly accounts for any loss of ad-
herent cells due to each experimental condition applied.
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Both modes of data expression gave qualitatively similar
results, and for the data and figures presented, values are
expressed per unit area, unless otherwise specified.
Antitissue factor assay
To determine that the factor Xa production measured
in HK-2 cells originated specifically from the activity
of tissue factor, control experiments were performed in
which HK-2 monolayers, were exposed to a given exper-
imental condition, then washed with Hepes buffer, and
incubated for 30 minutes at 37◦C with or without an IgG
murine monoclonal antibody against human tissue factor
(30 nmol/L to 300 nmol/L). Then, factor Xa production
was measured as described above.
Anti-TFPI assay
The possible role of cell-associated TFPI on tissue fac-
tor activity of HK-2 cells was also examined. After expo-
sure to a given experimental condition, HK-2 monolayers
were washed with Hepes buffer and then incubated for
30 minutes at 37◦C with or without an IgG rabbit poly-
clonal anti-TFPI antibody (67 nmol/L or 335 nmol/L).
Then, monolayers were assayed for factor Xa production
as described above.
Assay of caspase-3 activity
In order to examine whether caspase-3 was activated in
HK-2 cells by Shiga toxin-1, caspase-3 activity was mea-
sured using a commercially available kit. After incuba-
tion with or without 10−9 mol/L of Shiga toxin-1 for 22
hours and measurement of factor Xa production of the
remaining adherent cells, 1.5 × 106 control and 1.5 ×
106 Shiga toxin-1–treated HK-2 cells were lysed, and the
cytosolic extract was incubated for 120 minutes at 37◦C
with 200 pmol/L of caspase-3 (DEVD-pNA, the tetrapep-
tide Asp-Glu-Val-Asp conjugated to p-nitroanilide). Free
pNA cleaved by caspase-3 from the substrate was mea-
sured at 405 nm.
Caspase-3 activity was also assayed in cells that de-
tached after exposure of HK-2 monolayers to Shiga toxin-
1 (10−9 mol/L) for 22 hours.
Immunofluorescence for Shiga toxin-1 binding
Shiga toxin-1 binding to HK-2 cells was assessed by im-
munofluorescent staining with an IgG rabbit polyclonal
anti-Shiga toxin-1 antibody. HK-2 cells were incubated
with or without 10−9 mol/L of Shiga toxin-1 for 1 hour
at 37◦C. Then, cells were washed six times with Hepes
buffer, fixed with paraformaldehyde (4%) for 20 min-
utes, blocked with goat serum (10%) for 2 hours, and
incubated overnight at 4◦C with anti-Shiga toxin-1 anti-
body (dilution 1:1000). After washing with Hepes buffer,
a fluorescein isothiocyanate (FITC)-conjugated IgG goat
antirabbit secondary antibody was employed for 1 hour at
room temperature (dilution 1:500). As a control, primary
antibody was omitted from some wells. Fluorescence was
visualized by epifluorescence microscopy (Nikon Op-
tiphot microscope) (Garden City, NY, USA).
Statistical methods
All experiments were performed at least three times
with two wells for each experimental condition. Experi-
mental data are reported as (sample) mean ± standard
deviation. N refers to the number of samples per experi-
mental condition. The value for each sample, in turn, rep-
resents the average of four independent measurements
with coefficient of variation less than 5%.
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS, Chicago, IL, USA)
version 10.0 for Windows. All data were first tested for
normality using the Shapiro-Wilks W test for small and
medium samples and the Kolmogorov-Smirnov D test or
K-S Lilliefors test for large samples. Data were compared
using a one-way analysis of variance (ANOVA), followed
by a post hoc test when a significant difference was noted.
When the assumption of homogeneity of variance was
met by the Levene test of homogeneity of variance, the
Tukey honestly significant difference (HSD) test was used
if the sample sizes were equal, and the Tukey-Kramer test
if the sample sizes were unequal. When the assumption
of homogeneity of variance was not met, the Tamhane
T2 test was employed. Differences were considered sig-
nificant if the probability (P) value was less than 0.05.
Pearson’s correlation coefficient was computed for cor-
relation analysis.
RESULTS
Effect of Shiga toxin-1 on tissue factor activity and cell
detachment in HK-2 cells
Cell surface tissue factor activity (determined by cell
surface generation of factor Xa) was measured on HK-
2 monolayers by chromogenic assay. Exposure of HK-2
cells to Shiga toxin-1 (10−15 mol/L to 10−9 mol/L) resulted
in a marked up-regulation of cell surface tissue factor ac-
tivity in a concentration and time-dependent fashion, as
shown in Figure 1A. Unstimulated (control) HK-2 cells
demonstrated constitutive cell surface tissue factor ac-
tivity. Increased expression of tissue factor was evident
by 2 hours of exposure to Shiga toxin-1, became statisti-
cally significant at 6 hours (P < 0.001) and remained ele-
vated even after 96 hours of exposure. At all time points
beyond 4 hours of exposure to Shiga toxin-1 and at all
concentrations of Shiga toxin-1 tested, tissue factor ac-
tivity was statistically significant higher than constitutive
tissue factor expression. While control cells showed no
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Fig. 1. Effect of Shiga toxin-1 (Stx-1) on tis-
sue factor (TF) activity (A) and cell detach-
ment (B) in human kidney-2 (HK-2) cells.
Confluent HK-2 cells were exposed to Shiga
toxin-1 (10−15 mol/L to 10−9 mol/L) for 2, 4,
6, 8, 10, 12, 22, 48, 72, and 96 hours. Control
represents untreated cells. Factor Xa (FXa)
production was assessed by chromogenic as-
say. Factor Xa production is a measure of tis-
sue factor activity. Cell detachment was as-
sessed by counting the number of adherent
and detached cells. The cell number repre-
sents the number of adherent cells per well.
Data are expressed as mean ± standard devi-
ation. The number of samples ranged from 6 to
>35 per time point and concentration of Shiga
toxin-1 used. Two wells were used for each ex-
perimental condition in each separate experi-
ment. ∗Significantly different (P <0.001) from
control of the same time point; §Significantly
different (P < 0.01) from control of the same
time point.
detachment at any time point, Shiga toxin-1 treatment
markedly affected the confluence and adherence of HK-
2 cells. As shown in Figure 1B, cell detachment was Shiga
toxin dose and exposure time-related. For example, at
the highest dose of Shiga toxin-1 tested (10−9 mol/L), 22
hours of incubation caused 57% of cells to be detached,
while after 96 hours, 97% of cells had detached. A similar
time-dependent behavior of cell detachment was ob-
served for the lower doses of Shiga toxin-1 applied. Total
cell count per each well (adherent plus detached cells, des-
ignated 100%) was not statistically significant different
between control wells and Shiga toxin-1–treated wells. In
all cases, the cells that were floating in the supernatant
after exposure to Shiga toxin-1 were not necrotic, as con-
firmed by trypan blue staining. It seemed noteworthy that
the tissue factor up-regulation observed at 6 hours of
Shiga toxin-1 exposure was preceded by a statistically
significant degree (P < 0.01, Shiga toxin-1 10−9 mol/L
as compared to control) of HK-2 cell detachment noted
at 4 hours of exposure. After that time point, at all con-
centrations and time points tested, Shiga toxin-1 treat-
ment resulted in a statistically significant detachment of
HK-2 cells as compared to the number of cells in the
control wells. When we normalized tissue factor activity
with respect to residual adherent cell number, tissue fac-
tor activity was exponentially increased over time at all
concentrations of Shiga toxin-1 used.
HK-2 cells that detached after exposure of HK-2 mono-
layers to Shiga toxin-1 (10−9 mol/L) for 22 hours also ex-
pressed enhanced tissue factor activity (data not shown).
Treatment with TNF-a (20 ng/mL) also increased tissue
factor activity in HK-2 cells, but had no effect on their
confluence (data not shown).
Effect of mutant Shiga toxin-1 on tissue factor activity
and cell detachment in HK-2 cells
In order to confirm that the effect of N-glycosidase
activity of Shiga toxin-1 conferred by its active site is re-
sponsible for the up-regulation of tissue factor activity,
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Fig. 2. Effect of mutant Shiga toxin-1 (Stx-1) on tissue factor (TF) ac-
tivity (A) and cell detachment (B) in human kidney-2 (HK-2) cells. Con-
fluent HK-2 cells were exposed to mutant Shiga toxin-1 (10−15 mol/L to
10−9 mol/L) or (wild-type) Shiga toxin-1 (10−15 mol/L to 10−9 mol/L)
for 22 hours. Control represents untreated cells. Factor Xa (FXa) pro-
duction was assessed by chromogenic assay. Factor Xa production is
a measure of tissue factor activity. Cell detachment was assessed by
counting the number of adherent and detached cells. The cell number
represents the number of adherent cells per well. Data are expressed as
mean ± standard deviation. The N represents the number of samples
for each experimental condition. Two wells were used for each experi-
mental condition in each separate experiment. aSignificantly different
from control (P < 0.001); bSignificantly different from mutant Shiga
toxin-1 of the same concentration (P < 0.001).
we examined the response of HK-2 cells to mutant Shiga
toxin-1. Figure 2 shows the effect of mutant Shiga toxin-
1 versus (wild-type) Shiga toxin-1 on tissue factor ac-
tivity and cell detachment in HK-2 cells after 22 hours
of exposure. Mutant Shiga toxin-1 did not significantly
enhance tissue factor activity when used at concentra-
tions from 10−15 mol/L to 10−11 mol/L, and detectable
enhancement (3.2-fold) was observed only with 10−9
mol/L of mutant Shiga toxin-1 and was comparable to
that induced by 10−15 mol/L and 10−13 mol/L of (wild-
type) Shiga toxin-1. In the same experiments, 10−9 mol/L
of (wild-type) Shiga toxin-1 induced a 4.7-fold increase in
tissue factor activity (P < 0.001) (wild-type) Shiga toxin-
1 10−9 mol/L as compared to mutant Shiga toxin-1 10−9
mol/L.
Effect of Shiga toxin-1 on protein synthesis in HK-2 cells
As Shiga toxin is considered a ribotoxin and inhibitor of
eukaryotic protein synthesis by depurination of a single
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Fig. 3. Effect of Shiga toxin-1 (Stx-1) on protein synthesis in human
kidney-2 (HK-2) cells. Confluent HK-2 cells were exposed to (wild-
type) Shiga toxin-1 (10−13 mol/L to 10−9 mol/L) or mutant Shiga toxin-1
(10−11 mol/L) for 22 hours. Control represents untreated cells. Protein
synthesis was assessed by 3H-leucine incorporation. Data are expressed
as percent of control ± standard deviation. The number of samples for
each experimental condition is eight. In each experiment, two wells
were used for each experimental condition. aSignificantly different from
control (P < 0.001); bSignificantly different from mutant Shiga toxin-1
(P < 0.001).
adenine residue from the 28S RNA component of the
ribosome, we determined whether Shiga toxin-1 caused
inhibition of protein synthesis by assaying the incorpora-
tion of 3H-leucine into total cellular protein. As shown
in Figure 3, exposure to (wild-type) Shiga toxin-1 dose-
dependently inhibited protein synthesis by HK-2 cells
while treatment with mutant Shiga toxin-1 or TNF-a did
not have an effect on protein synthesis.
Effect of concurrent stimulation with TNF-a and Shiga
toxin-1 on tissue factor activity and cell detachment in
HK-2 cells
Since certain cytokines including TNF-a have been re-
ported as involved in the pathogenesis of HUS, we tested
whether TNF-a could influence tissue factor enhance-
ment and cell detachment induced by Shiga toxin-1 in
HK-2 cells. As shown in Figure 4A, coincubation for
22 hours of TNF-a (20 ng/mL) with Shiga toxin-1 (10−15
mol/L to 10−9 mol/L) induced an increase in tissue fac-
tor production, as compared to that induced by Shiga
toxin-1 alone. As depicted in Figure 4B, TNF-a alone
did not cause any cell detachment, though concurrent
incubation of HK-2 cells with TNF-a and Shiga toxin-1
(10−15 mol/L to 10−9 mol/L) for 22 hours, enhanced cell
detachment caused by Shiga toxin-1 alone [P < 0.001,
TNF-a + Shiga toxin-1 (10−15 mol/L to 10−9 mol/L) as
compared to Shiga toxin-1 (10−15 mol/L to 10−9 mol/L)
alone]. The higher the dose of Shiga toxin-1, the greater
the cell detachment caused by costimulation with TNF-
a. Taking into account the effect of cell detachment and
by normalizing tissue factor activity to residual adherent
cell number, the costimulation of cells with TNF-a (20
ng/mL) and Shiga toxin-1 increased tissue factor activity
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Fig. 4. Effect of concurrent stimulation with
tumor necrosis factor-a (TNF-a) and Shiga
toxin-1 (Stx-1) on tissue factor (TF) activ-
ity (A) and cell detachment (B) in human
kidney-2 (HK-2) cells. Confluent HK-2 cells
were exposed to Shiga toxin-1 (10−15 mol/L
to 10−9 mol/L) with or without concomitant
stimulation with TNF-a (20 ng/mL) for 22
hours. Factor Xa (FXa) production was as-
sessed by chromogenic assay. Factor Xa pro-
duction is a measure of tissue factor activ-
ity. Cell detachment was assessed by count-
ing the number of adherent and detached
cells. The cell number represents the num-
ber of adherent cells per well. Data are ex-
pressed as mean ± standard deviation. The
number of samples is 12 for controls (unstim-
ulated cells) and TNF-a alone and six for the
remainder of experimental conditions. Two
wells were used for each experimental condi-
tion in each experiment. aSignificantly differ-
ent from control; bSignificantly different from
Shiga toxin-1 alone of the same concentration;
cSignificantly different from TNF-a alone. No
asterisk denotes P < 0.05; ∗P < 0.01; ∗∗P <
0.001.
(measured in fmol/minute × 100,000 cells) from 2.5-fold
(TNF-a + Shiga toxin-1 10−15 mol/L) to five-fold (TNF-
a + Shiga toxin-1 10−9 mol/L) in comparison with the
levels of tissue factor activity in cells treated with Shiga
toxin-1 alone. For all Shiga toxin-1 doses used in com-
bination with TNF-a, this up-regulation was statistically
significantly different from tissue factor activity produced
by TNF-a alone.
Up-regulation of tissue factor activity is partially depen-
dent on the PKC pathway in HK-2 cells
Figure 5 shows that calphostin C (10−6 mol/L), a se-
lective PKC pathway inhibitor, partially inhibited the
up-regulation of tissue factor activity by 10−9 mol/L of
Shiga toxin-1 in HK-2 cells. Shiga toxin-1 (10−9 mol/L)
up-regulated tissue factor activity 3.8-fold at 22 hours of
exposure as compared to control cells, whereas calphostin
C reduced this up-regulation to 2.1-fold (P < 0.001, Shiga
toxin-1 10−9 mol/L as compared to Shiga toxin-1 10−9
mol/L + calphostin C 10−6 mol/L). However, this reduced
up-regulation was still significantly different from tissue
factor expression in control cells (P < 0.001, Shiga toxin-
1 10−9 mol/L + calphostin C 10−6 mol/L as compared
to control). Calphostin C did not affect the constitutive
tissue factor activity of control HK-2 cells. The phorbol
ester PMA was used as a positive control, since this com-
pound has been shown to enhance transcription of the
tissue factor gene and is an agonist of the PKC pathway.
PMA significantly increased baseline expression of tis-
sue factor, and this increase was completely abrogated
by calphostin C. The presence of calphostin C did not af-
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Fig. 5. Up-regulation of tissue factor (TF) activity is partially depen-
dent on the protein kinase C (PKC) pathway in human kidney-2 (HK-2)
cells. Confluent HK-2 cells were exposed to Shiga toxin-1 (Stx-1) (10−9
mol/L) and phorbol myristate acetate (PMA) (10−8 mol/L) for 22 hours
with or without calphostin C (10−6 mol/L). Calphostin C blocks the PKC
pathway. Factor Xa (FXa) production was assessed by chromogenic as-
say. Factor Xa production is a measure of tissue factor activity. Data
are expressed as mean ± standard deviation. The number of samples
for each experimental condition is six. In each experiment, two wells
were used for each experimental condition. aSignificantly different from
control without calphostin C (P < 0.001); bSignificantly different from
Shiga toxin-1 + calphostin C (P < 0.001); cSignificantly different from
control + calphostin C (P < 0.001); dSignificantly different from PMA
(P < 0.001); eSignificantly different from PMA + calphostin C (P <
0.001).
fect the cell detachment induced by 10−9 mol/L of Shiga
toxin-1 (59% with Shiga toxin-1 10−9 mol/L + calphostin
C 10−6 mol/L versus 60% with Shiga toxin-1 10−9 mol/L
alone).
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Fig. 6. Effect of antitissue factor (anti-TF) monoclonal antibody on
tissue factor activity in human kidney-2 (HK-2) cells. HK-2 cells were
incubated with antitissue factor antibody (30 nmol/L to 300 nmol/L)
for 30 minutes, after 22 hours’ incubation with or without Shiga toxin-
1 (Stx-1) (10−9 mol/L). Factor Xa (FXa) production was assessed by
chromogenic assay. Factor Xa production is a measure of tissue factor
activity. Data are expressed as mean ± standard deviation. The number
of samples is 16 in the case of the control and Shiga toxin-1 (10−9 mol/L)
without incubation with antitissue factor antibody, and ten in the case of
the control and Shiga toxin-1 (10−9 mol/L) with incubation with each
concentration of antitissue factor antibody. In each experiment, two
wells were used for each experimental condition. aSignificantly different
from control; bSignificantly different from Shiga toxin-1. No asterisk
denotes P < 0.05; ∗P < 0.01; ∗∗P < 0.001.
Effect of antitissue factor monoclonal antibody on tissue
factor activity in HK-2 cells
To demonstrate that the baseline and the induced fac-
tor Xa production measured was attributable to the pres-
ence of tissue factor per se, we used an antitissue factor
murine monoclonal antibody to inhibit factor Xa pro-
duction. As can be seen in Figure 6, 100 nmol/L and 200
nmol/L of antitissue factor antibody reduced constitutive
functional tissue factor activity by 87% and 93%, respec-
tively, in control HK-2 cells (P < 0.001) (control as com-
pared to control + 100 nmol/L or 200 nmol/L antitissue
factor antibody). In HK-2 cells exposed to Shiga toxin-
1 (10−9 mol/L) for 22 hours, 30 nmol/L to 300 nmol/L of
antitissue factor antibody reduced Shiga toxin-1–induced
tissue factor activity by 73% to 85% (P < 0.001) (Shiga
toxin-1 10−9 mol/L + 30 nmol/L to 300 nmol/L an-
titissue factor antibody as compared to Shiga toxin-1
10−9 mol/L).
Effect of anti-TFPI polyclonal antibody on tissue factor
activity in HK-2 cells
As shown in Figure 7, the addition of 67 nmol/L and 335
nmol/L of anti-TFPI polyclonal antibody in unstimulated
HK-2 cells augmented the constitutive factor Xa produc-
tion by three- and 3.8-fold, respectively (P < 0.001) (con-
trol + 67 nmol/L or 335 nmol/L anti-TFPI antibody as
compared to control). This finding strongly suggests that
HK-2 cells produce TFPI. Tissue factor activity observed
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Fig. 7. Effect of antitissue factor pathway inhibitor (anti-TFPI) poly-
clonal antibody on tissue factor (TF) activity in human kidney-2 (HK-2)
cells. HK-2 cells were incubated with anti-TFPI antibody (67 nmol/L or
335 nmol/L) for 30 minutes, after 22 hours’ incubation with or without
Shiga toxin-1 (Stx-1) (10−9 mol/L). Factor Xa (FXa) production was
assessed by chromogenic assay. Factor Xa production is a measure of
tissue factor activity. Data are expressed as mean ± standard devia-
tion. The number of samples for each experimental condition is six. In
each experiment, two wells were used for each experimental condition.
aSignificantly different from control (P < 0.001); bSignificantly differ-
ent from control + 67 nM anti-TFPI polyclonal antibody (P < 0.001);
cSignificantly different from Shiga toxin-1 (P < 0.001).
with 67 nmol/L of anti-TFPI antibody was not statistically
significantly different from that induced by 10−9 mol/L of
Shiga toxin-1 for 22 hours. This observation indicates that
Shiga toxin-1 could exert some of its effect by inhibiting
TFPI activity. Nonetheless, the use of 67 nmol/L and 335
nmol/L of anti-TFPI antibody in HK-2 cells exposed to
Shiga toxin-1 (10−9 mol/L) for 22 hours increased tissue
factor activity by 41% and 44%, respectively. These find-
ings suggest that residual TFPI activity is still present
on HK-2 cells subjected to exposure to Shiga toxin-1
(P < 0.001) (Shiga toxin-1 10−9 mol/L + 67 nmol/L or 335
nmol/L anti-TFPI antibody as compared to Shiga toxin-1
10−9 mol/L alone).
Caspase-3 activity and effect of the general caspase
inhibitor Z-VAD-FMK on Shiga toxin-1–induced
up-regulation of tissue factor activity and cell detachment
in HK-2 cells
Caspase-3 is a central molecule in the apoptotic path-
way. HK-2 cells were incubated with or without Shiga
toxin-1 (10−9 mol/L) for 22 hours and after measurement
of factor Xa production, adherent cells were assayed for
caspase-3 activity. This activity was found to be increased
2.2-fold in Shiga toxin-1 treated HK-2 cells as compared
to control cells (P < 0.05), indicating that Shiga toxin-1
induced apoptosis in HK-2 cells via a caspase-3 depen-
dent pathway. Concomitantly, this increase in caspase-3
activity was correlated with a simultaneous 3.9-fold in-
crease in tissue factor activity. There was a highly signif-
icant positive correlation (r = 0.95, P < 0.01) between
tissue factor surface activity and caspase-3 activity; the
higher the fold increase in caspase-3 activity, the higher
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Fig. 8. Effect of the general caspase inhibitor Z-VAD-FMK on Shiga toxin-1 (Stx-1)–induced up-regulation of tissue factor (TF) activity (A)
and cell detachment (B) in human kidney-2 (HK-2) cells. Confluent HK-2 cells were exposed to Shiga toxin-1 (10−13 mol/L to 10−9 mol/L) with
or without Z-VAD-FMK (40 lmol/L to 100 lmol/L) for 22 hours. Factor Xa (FXa) production was assessed by chromogenic assay. Factor Xa
production is a measure of tissue factor activity. Cell detachment was assessed by counting the number of adherent and detached cells. The cell
number represents the number of adherent cells per well. Data are expressed as mean ± standard deviation. The N represents the number of samples
for each experimental condition. Two wells were used for each experimental condition in each experiment. aSignificantly different from control with
or without Z-VAD-FMK; bSignificantly different from Shiga toxin-1 of the same concentration + 40 lmol/L Z-VAD-FMK; cSignificantly different
from Shiga toxin-1 of the same concentration + 80 lmol/L Z-VAD-FMK; dSignificantly different from Shiga toxin-1 of the same concentration +
100 lmol/L Z-VAD-FMK. No asterisk denotes P < 0.05; ∗P < 0.01; ∗∗P < 0.001.
the up-regulation of tissue factor activity in HK-2 cells
treated with Shiga toxin-1 (10−9 mol/L) for 22 hours.
Detached HK-2 cells after treatment of HK-2 mono-
layers with Shiga toxin-1 (10−9 mol/L) for 22 hours were
also found to have increased caspase-3 activity (data not
shown).
In order to examine further whether the processes of
apoptosis and tissue factor up-regulation were linked,
HK-2 monolayers were exposed to Shiga toxin-1 (10−13
mol/L to 10−9 mol/L) for 22 hours with or without the
presence of the general caspase inhibitor Z-VAD-FMK.
Figure 8 shows that coincubation of HK-2 cells with Shiga
toxin-1 (10−13 mol/L to 10−9 mol/L) and the general cas-
pase inhibitor Z-VAD-FMK (40 lmol/L to 100 lmol/L)
for 22 hours significantly decreased tissue factor activity
and prevented cell detachment in comparison with Shiga
toxin-1–treated cells (P < 0.001). Neither dimethyl sul-
foxide (DMSO) (that was used as a diluent for Z-VAD-
FMK) nor Z-VAD-FMK affected the constitutive tissue
factor activity and confluence of HK-2 cells.
Shiga toxin-1 binding to HK-2 cells
Since human PTECs have been reported to express
cell surface Gb3 receptors, we investigated whether Shiga
toxin-1 binds to HK-2 cells. As shown in Figure 9A,
anti-Shiga toxin-1 antibody labeling of HK-2 cells prein-
cubated with Shiga toxin-1 was demonstrated by im-
munofluorescence. HK-2 cells not treated with Shiga
toxin-1, on the other hand, failed to react with anti-Shiga
toxin-1 antibody. The positive immunofluorescence of
Shiga toxin-1–treated HK-2 cells with anti-Shiga toxin-
1 antibody is considered to reflect specific binding of
Shiga toxin-1 to HK-2 cells. In the absence of primary
Nestoridi et al: Stx-1 up-regulates tissue factor activity on PTECs 2263
Fig. 9. Shiga toxin-1 (Stx-1) binding to hu-
man kidney-2 (HK-2) cells, as demonstrated
by positive immunofluorescent labeling (A).
No Shiga toxin-1 binding to HK-2 cells in the
absence of primary antibody (B).
anti-Shiga toxin-1 antibody but in the presence of sec-
ondary antibody, no visible immunofluorescence was ob-
served (Fig. 9B).
DISCUSSION
The present study demonstrates that HK-2 cells ex-
press tissue factor constitutively, as is characteristic of
extravascular cell types such as fibroblasts, pericytes,
smooth muscle cells, and other epithelial cells not nor-
mally in contact with blood [23, 28]. Our data also indi-
cate that HK-2 cells express TFPI, the main regulator of
tissue factor activity. The principal finding of this study is
that Shiga toxin, in a dose- and time-dependent manner
increases HK-2 cell surface tissue factor activity. The data
also demonstrate that Shiga toxin induces detachment of
HK-2 cells and inhibition of protein synthesis in parallel
with Shiga toxin–mediated augmentation of tissue factor
activity.
When HK-2 cells were treated with Shiga toxin, in-
tracellular caspase-3 activity increased, suggesting that
HK-2 cell detachment involves apoptosis. Accordingly,
the significant positive correlation between increase in
caspase-3 activity and up-regulation in tissue factor ac-
tivity and the fact that the general caspase inhibitor
Z-VAD-FMK significantly reduced both Shiga toxin–
induced tissue factor up-regulation and HK-2 cell detach-
ment, suggest that apoptosis of HK-2 cells may be directly
linked to the up-regulation of their tissue factor activity.
Numerous studies indicate that human renal PTECs
undergo apoptosis when exposed to Shiga toxin [19, 20,
22]. The initiation of apoptosis leads to rapid loss of
phospholipid asymmetry in cell membrane, with subse-
quent redistribution of phosphatidylserine to the outer
leaflet [29]. The presence of phospholipids, particu-
larly phosphatidylserine, is considered critically impor-
tant for the activity of the complex formed between
tissue factor, factor VII/VIIa, and factor X [30]. In a
purified system, the addition of appropriate phospho-
lipids enhanced the rate of factor X activation more than
100-fold [31]. Exposing cells that express tissue factor to
successive freeze-thaw cycles, calcium ionophore, or cy-
cloheximide is known to increase tissue factor activity
without increasing synthesis of tissue factor mRNA or
protein [29, 32, 33]. Aortic smooth muscle cells, mesan-
gial cells, fibroblasts, and endothelial cells that have
undergone apoptosis increase their surface tissue factor
activity [33–35]. Sugiyama et al [36] recently reported
that hypochlorous acid, a macrophage product, induces
endothelial apoptosis and tissue factor expression, while
Hutter et al [37] provided evidence that apoptotic cell
death of macrophages is linked to the expression of tis-
sue factor in lipid-rich plaques.
Our data suggest that the PKC pathway may be in-
volved in tissue factor augmentation in Shiga toxin–
treated HK-2 cells. However, this augmentation is only
partially dependent upon this pathway, since calphostin
C, which blocks PKC, blunts this increase. These data im-
ply that Shiga toxin might directly activate the PKC path-
way, subsequently activating nuclear factor-jB (NF-jB),
and increasing tissue factor expression. The promoter site
of the tissue factor gene contains a NF-jB binding site
[38], and TNF-a activates tissue factor gene transcription
in endothelial cells through an increase in binding of NF-
jB to the tissue factor promoter [39]. The activation of the
PKC pathway has been reported to be essential in Shiga
toxin–mediated signaling for TNF-a production [40], and
Lang et al [35] reported that the induction of tissue factor
in mesangial cells in response to inflammatory mediators
is PKC pathway dependent.
Mutant Shiga toxin neither enhanced HK-2 cell surface
tissue factor activity nor caused HK-2 cell detachment
to the same extent as (wild-type) Shiga toxin, consistent
with reduced activity of the mutant. This observation also
suggests that the N-glycosidase enzymatic activity of the
A subunit of Shiga toxin is necessary for tissue factor
up-regulation and cell detachment, providing further ev-
idence that these two events are interrelated.
TNF-a and Shiga toxin showed a synergistic effect on
tissue factor enhancement in HK-2 cells that was also
correlated with increased HK-2 cell detachment, and
might explain the importance of cytokine induction in
the pathophysiology of HUS. Elevated plasma and uri-
nary concentrations of TNF-a, IL-6, and IL-8 have been
demonstrated in HUS patients [41, 42] and many in vitro
studies have indicated that inflammatory cytokines po-
tentiate the effects of Shiga toxin [12, 13]. Karpman
et al [43] showed that prestimulation of renal tubular
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epithelial cells with TNF-a enhanced the apoptosis-
inducing effect of Shiga toxin, whereas exposure to TNF-
a alone did not lead to apoptosis.
The increased tissue factor activity in HK-2 cells af-
ter Shiga toxin exposure might also result from di-
minished activity of HK-2 cell surface–associated TFPI.
HK-2 cells express both tissue factor and TFPI, which
could be involved in the regulation of hemostasis and
coagulation in the tubulointerstitium during renal injury
[24]. Unstimulated cells and Shiga toxin–treated cells
exposed to the highest concentration of anti-TFPI an-
tibody exhibited no difference in tissue factor activity.
This observation suggests that the constitutive expression
of cell surface tissue factor activity is normally down-
regulated by the presence of TFPI and that treatment
with Shiga toxin might inhibit synthesis of TFPI or loss
of its association with the HK-2 cell surface, thus causing
up-regulation of tissue factor activity.
Although it is generally accepted that endothelial cell
damage mediated by Shiga toxin is the major event
triggering the development of HUS [44], the proximal
tubule is an emerging target of Shiga toxin action [18–
21]. Marked elevation of N-acetyl glucosaminidase and
b 2-microglobulin, both of which are specific markers of
tubular function, has provided evidence of renal tubu-
lar damage in the acute stage of HUS [21]. In a murine
model, injection of Shiga toxin and oral administration of
Shiga toxin–producing E. coli damaged the renal tubular
epithelium, while glomeruli remain unaffected [45–47].
In studies with the baboon model of HUS, Taylor et al
[48] observed that the most severely affected segment of
the nephron was the proximal tubule.
In addition to renal arteriolar and glomerular endothe-
lial cells, renal proximal and distal tubules, as well as
mesangial renal cells and glomerular epithelial cells have
been reported to express Gb3 receptors and bind Shiga
toxin [16, 17, 49]. The present study also demonstrates
that Shiga toxin binds to HK-2 cells. Uchida et al [50] ob-
served that bound Shiga toxin was present in the distal
tubules in frozen renal autopsy tissue from a child who
died from HUS. Their observation suggests that circu-
lating Shiga toxin is delivered to the kidney and binds
to renal tubules during Shiga toxin–producing E. coli
infection.
Human proximal tubular cells are highly sensitive to
Shiga toxin and, in contrast to endothelial cells, an-
tecedent exposure to inflammatory agents such as TNF-a
or IL-1 is not required [12, 13, 18–22, 43]. The present
study clearly shows that tissue factor activity on HK-2
cells increases after exposure to Shiga toxin. We thus
speculate that proximal tubular cells are an early target
for Shiga toxin–mediated injury and that the increase in
tissue factor expression might initiate activation of the
coagulation pathway, provided that glomerular injury or
injury to peritubular capillaries is sufficiently severe to
permit access of plasma and/or whole blood to the prox-
imal tubules. Furthermore, detachment of the proximal
tubular cells (along with platelet-fibrin thrombi produced
by their tissue factor up-regulation) might contribute to
tubular occlusion and the development of acute renal fail-
ure. The tissue factor up-regulation could also account for
the tubular atrophy with tubulointerstitial fibrosis that
has been described as a late histopathologic finding in
patients who survive severe episodes of HUS with pro-
longed anuria and are at increased risk for chronic renal
insufficiency [49, 51]. Tissue factor is also considered a
member of the cytokine receptor family and can regu-
late immune/inflammation responses either directly or
through generation of factor Xa, thrombin, and fibrin
[52, 53]. An increase in tissue factor on proximal tubu-
lar cells could lead to recruitment of inflammatory cells
and/or release of inflammatory cytokines that could al-
ter the cytokine milieu and thus, the adjacent function of
glomerular endothelial cells by modulating their expres-
sion of Gb3 receptors, their susceptibility to Shiga toxin
and favoring a procoagulant phenotype by enhancement
of their functional tissue factor. Also, in case of severe
tubular occlusion, a reversal of flow from the tubules
to glomerulus might be possible. The combination of
these events could explain the formation of platelet-fibrin
thrombi and the development of acute renal failure ob-
served in HUS.
CONCLUSION
The present study shows that HK-2 cells undergoing
apoptosis upon exposure to Shiga toxin increase their tis-
sue factor surface activity. We speculate that tissue factor
up-regulation may occur in proximal tubular cells in vivo
in response to Shiga toxin, and may contribute to the pro-
coagulant activity, inflammation, and acute renal failure
observed in HUS.
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